Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib combinations in pediatric and young adult relapsed/refractory solid tumors
jRCT2031210562Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of abemaciclib, temozolomide and irinotecan in Nonhematologic neoplasms and central nervous system tumor (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with dose-limiting toxicities, Mean steady state concentrations of abemaciclib and 2 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
abemaciclibtemozolomideirinotecan
03
Conditions
Nonhematologic neoplasmscentral nervous system tumor
Beyond the preview
Go deeper on jRCT2031210562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210562.